RAFAEL HOLDINGS, INC. Proceeds from Sale of Productive Assets
RAFAEL HOLDINGS, INC. (RFL) reported Proceeds from Sale of Productive Assets of $49.40 million for the 12-month period ending 2023-07-31, per its 10-K/A filed 2024-12-20.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2024-12-20
- RAFAEL HOLDINGS, INC. proceeds from sale of productive assets for the quarter ending 2023-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. proceeds from sale of productive assets for fiscal 2023 was $49.40M.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|
| 2023-07-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $49.40M 10-K/A · filed 2024-12-20 | |
| 2023-04-30 | $49.40M 10-Q · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |